Answers are grounded in this paper and cite their sources.
Methotrexate (MTX) is an essential chemotherapeutic agent for the treatment of neoplastic diseases. It has substantially contributed to the decrease of central nervous system (CNS) and testicular relapses in childhood acute lymphoblastic leukemia (ALL) and thus to the remarkably improved prognosis of this disease. However, intensive MTX-treatment bears considerable risk of acute and delayed toxicity, for example, mucositis, myelosuppression, renal dysfunction, and CNS toxicity. CNS abnormalities occur in a substantial number of patient's either on nuclear magnetic resonance (NMR) imaging alone or with clinical manifestations. These mainly comprise aseptic meningitis, transverse myelopathy, stroke-like syndrome, and acute or chronic encephalopathy Our experience with an adolescent who developed subacute leukencephalopathy after initial intrathecal MTX administration for ALL is instructive.
No takes yet. Share an insight, caveat, or question.
Strunk et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: